| Wang, Changli |
RATIONALE-315, NCT04379635: Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 453 | RoW | Tislelizumab, BGB-A317, Cisplatin injection, Paclitaxel injection, Pemetrexed Disodium, Placebos, Carboplatin | BeiGene | Non Small Cell Lung Cancer | 06/25 | 11/25 | | |
|
| Recruiting | 3 | 390 | RoW | Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, Experimental, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection, Active Comparator | 3D Medicines (Sichuan) Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 09/27 | | |
NCT04965831: Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) |
|
|
| Not yet recruiting | 2 | 40 | NA | Furmonertinib, AST2818 | Tianjin Medical University Cancer Institute and Hospital, Allist Pharmaceuticals, Inc. | Lung Adenocarcinoma | 03/23 | 05/26 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05088967: Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer |
|
|
| Terminated | 1 | 6 | RoW | IBI110, sintilimab | Innovent Biologics (Suzhou) Co. Ltd. | Non-small Cell Lung Cancer (NSCLC) | 12/21 | 12/23 | | |
| Kan, Xuefeng |
| No trials found |
